Welcome to the Discoveries from AHA: PCI-STEMI Resource Center. This resource center provides take-home messages from the 2016 American Heart Association Scientific Sessions on topics related to recent advances in PCI-STEMI via coverage of sessions on treatment options – including bivalirudin, prasugrel and tirofiban – and interviews with leading clinicians. Bookmark this page and visit often to hear experts provide context on the major findings presented on updates in percutaneous coronary intervention, including results of the PIONEER AF-PCI trial, which demonstrated rivaroxaban conferred less bleeding risk than warfarin in patients with atrial fibrillation undergoing PCI with stenting. In addition, view new analyses of the TAO trial, which has previously demonstrated that otamixaban did not reduce ischemic events, but did increase bleeding in patients with non-ST-elevation ACS, and the ARISTOTLE trial, which has demonstrated that major bleeding was associated with increased risk for death, ischemic stroke and MI, and the risk was similarly elevated regardless of treatment with warfarin or apixaban.